Anti-SGK1 antibody
3
(4 Reviews)
|
(20 Publications)
Rabbit Polyclonal SGK1 antibody. Suitable for WB, ICC/IF and reacts with Mouse, Human samples. Cited in 20 publications.
View Alternative Names
SGK, SGK1, Serine/threonine-protein kinase Sgk1, Serum/glucocorticoid-regulated kinase 1
- ICC/IF
Lab
Immunocytochemistry/ Immunofluorescence - Anti-SGK1 antibody (AB43606)
ICC/IF image of ab43606 stained HeLa cells. The cells were 100% methanol fixed (5 min) then permeabilised using 0.1% PBS-Triton and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to further permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody ab43606 at 5μg/ml overnight at +4°C. The secondary antibody (pseudo-colored green) was Alexa Fluor® 488 goat anti- rabbit (ab150081) IgG (H+L) preadsorbed, used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (pseudo-colored red) at a 1/200 dilution for 1h at room temperature. DAPI was used to stain the cell nuclei (pseudo-colored blue) at a concentration of 1.43μM for 1hour at room temperature.
- WB
Ap19106****
Western blot - Anti-SGK1 antibody (AB43606)
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab43606 overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP, and visualised using ECL development solution ab133406.
All lanes:
Western blot - Anti-SGK1 antibody (ab43606) at 1 µg/mL
Lane 1:
Human BT549 (Breast carcinoma cell line) Whole Cell Lysate at 10 µg
Lane 2:
Western blot - T-47D whole cell lysate (<a href='/en-us/products/cell-lysates/t-47d-whole-cell-lysate-ab14899'>ab14899</a>) at 10 µg
Lane 3:
A431 (Human epithelial carcinoma cell line) Whole Cell Lysate at 10 µg
Secondary
All lanes:
Goat Anti-Rabbit IgG H&L (HRP) preadsorbed at 1/50000 dilution
Predicted band size: 48 kDa
Observed band size: 49 kDa
true
Exposure time: 1min
- WB
Ap19106****
Western blot - Anti-SGK1 antibody (AB43606)
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 2% Bovine Serum Albumin before being incubated with ab43606 overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP, and visualised using ECL development solution ab133406.
All lanes:
Western blot - Anti-SGK1 antibody (ab43606) at 1 µg/mL
Lane 1:
HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate at 10 µg
Lane 2:
Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate at 10 µg
Lane 3:
NIH 3T3 (Mouse embryonic fibroblast cell line) Whole Cell Lysate at 10 µg
Lane 4:
Human pancreas tissue lysate - total protein (<a href='/en-us/products/unavailable/human-pancreas-tissue-lysate-total-protein-ab29816'>ab29816</a>) at 10 µg
Lane 5:
Lung (Human) Tissue Lysate at 10 µg
Lane 6:
Human brain tissue lysate - total protein (<a href='/en-us/products/unavailable/human-brain-tissue-lysate-total-protein-ab29466'>ab29466</a>) at 10 µg
Secondary
All lanes:
Goat Anti-Rabbit IgG H&L (HRP) preadsorbed at 1/50000 dilution
Predicted band size: 48 kDa
Observed band size: 38 kDa,49 kDa,51 kDa,60 kDa,95 kDa
true
Exposure time: 5s
- WB
CiteAb
Western blot - Anti-SGK1 antibody (AB43606)
SGK1 western blot using anti-SGK1 antibody ab43606. Publication image and figure legend from Evans, R. D. R., Antonelou, M., et al., 2020, Nat Commun, PubMed 32868758.
ab43606 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab43606 please see the product overview.
Expression of the components of the intracellular pathway that mediate salt-driven IL-17 inflammation and salt rescue of in vitro IL-17 responses in salt-losing tubulopathy patients.a IL-23 receptor expression on unstimulated CD4+ cells in healthy controls (n = 8) and SLT patients (n = 7) : HC 0.42% (0.34–1.01), SLT 0.79% (0.73–2.60), p = 0.07. Groups are compared with a two-sided Mann–Whitney test. Error bars represent interquartile range around the median. b IL-23 receptor expression on unstimulated CD4− cells in healthy controls (n = 8) and SLT patients (n = 7) : HC 3.34% (2.26–6.56), SLT 9.67% (5.64–10.65), p = 0.02. Groups are compared with a two-sided Mann–Whitney test. Error bars represent interquartile range around the median. c Relative lymphocyte NFAT5 expression in healthy controls (n = 13) and SLT patients (n = 11) : HC 1.01 AU (0.70–1.95), SLT 1.10 AU (0.76–1.62), p = 0.85. Groups are compared with a two-sided Mann–Whitney test. Error bars represent interquartile range around the median. d Relative lymphocyte SGK1 expression in healthy controls (n = 7) and SLT patients (n = 13) : relative intensity HC = 1.07 AU (0.73–1.2), SLT = 1.09 AU (0.80–1.31), p = 0.70. Groups are compared with a two-sided Mann–Whitney test. Error bars represent interquartile range around the median. e Representative western blot of SGK1 expression in HCs and SLT patients. SGK1 expression was determined in SLT patients (n = 13) and healthy controls (n = 7) across three experiments. f Th17 polarisation in HC (n = 27) and SLT patients (n = 25) in standard media, and in SLT patients in media supplemented with 40 mM NaCl : HC + 0 mM NaCl 3.2% (2.5–6.3); SLT + 0 mM NaCl 1.6% (0.8–2.0); SLT + 40 mM NaCl 3.1% (2.4–5.3); p = <0.0001. Groups are compared using a Kruskal–Wallis test with Dunn’s multiple comparison testing (shown with significance bars). Error bars represent interquartile range around the median. g Tc17 polarisation in HC (n = 27) and SLT patients (n = 25) in standard media, and in SLT patients in media supplemented with 40 mM NaCl : HC + 0 mM NaCl 1.5% (0.6–3.0); SLT + 0 mM NaCl 0.6% (0.3–1.1); SLT + 40 mM NaCl 1.6% (0.9–3.1); p = 0.0007; groups are compared using a Kruskal–Wallis test with Dunn’s multiple comparison testing (shown with significance bars). Error bars represent interquartile range around the median. ns not significant (p > 0.05), *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. HC healthy control, SLT salt-losing tubulopathy, AU arbitrary units. Source data are provided as a Source data file.
false
Reactivity data
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
SGK1 regulates ion transport cell proliferation and survival pathways. SGK1 is not usually part of large protein complexes but interacts dynamically with other proteins to exert its effects. It plays a major role in regulating sodium channels in the kidney therefore modulating sodium balance and blood pressure. It also affects various cell survival mechanisms influencing cell growth and apoptosis in response to physiological cues.
Pathways
SGK1 is involved in the PI3K/AKT/mTOR signaling pathway and the WNK/SPAK pathway. These pathways influence cellular growth metabolism and ion transport. SGK1 shares pathway relevance with proteins like AKT1 and mTOR in the PI3K/AKT/mTOR axis impacting various metabolic and growth-related cellular processes. In the WNK/SPAK pathway SGK1 regulates ion channels in collaboration with WNK kinases affecting electrolyte balance.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (20)
Recent publications for all applications. Explore the full list and refine your search
BMC medicine 20:309 PubMed36068525
2022
Applications
Unspecified application
Species
Unspecified reactive species
IUBMB life 74:463-473 PubMed35148462
2022
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in molecular neuroscience 14:798261 PubMed34899186
2021
Applications
Unspecified application
Species
Unspecified reactive species
iScience 24:103487 PubMed34934913
2021
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in cell and developmental biology 9:751012 PubMed34869338
2021
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in oncology 11:752573 PubMed34868959
2021
Applications
Unspecified application
Species
Unspecified reactive species
FEBS open bio 11:1395-1405 PubMed33728820
2021
Applications
Unspecified application
Species
Unspecified reactive species
Arthritis research & therapy 23:78 PubMed33750441
2021
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 11:4368 PubMed32868758
2020
Applications
Unspecified application
Species
Unspecified reactive species
FASEB journal : official publication of the Federa 34:5363-5388 PubMed32067272
2020
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com